The top 1% of companies spend thousands of hours building their own feature flagging and A/B testing platforms in-house. The other 99% are left paying for expensive 3rd party SaaS tools or hacking ...
Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX® ) and mFOLFOX6 ...